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In acute myeloid leukemia (AML) internal tandem duplications of the FLT3 gene (FLT3-ITD) are associated with poor prognosis.
Retrospectively, we investigated the prognostic and predictive impact of FLT3-ITD insertion site (IS) in 452 patients randomized
within the RATIFY trial, which evaluated midostaurin additionally to intensive chemotherapy. Next-generation sequencing
identified 908 ITDs, with 643 IS in the juxtamembrane domain (JMD) and 265 IS in the tyrosine kinase domain-1 (TKD1). According
to IS, patients were categorized as JMDsole (n= 251, 55%), JMD and TKD1 (JMD/TKD1; n= 117, 26%), and TKD1sole (n= 84, 19%).
While clinical variables did not differ among the 3 groups, NPM1 mutation was correlated with JMDsole (P= 0.028). Overall survival
(OS) differed significantly, with estimated 4-year OS probabilities of 0.44, 0.50, and 0.30 for JMDsole, JMD/TKD1, and TKD1sole,
respectively (P= 0.032). Multivariate (cause-specific) Cox models for OS and cumulative incidence of relapse using allogeneic
hematopoietic cell transplantation (HCT) in first complete remission as a time-dependent variable identified TKD1sole as
unfavorable and HCT as favorable factors. In addition, Midostaurin exerted a significant benefit only for JMDsole. Our results




Internal tandem duplications of the FLT3 gene (FLT3-ITD), resulting
in duplication of 3 to more than hundreds of nucleotides, are
present in ~25% of younger adults with newly diagnosed acute
myeloid leukemia (AML) [1–4]. The FLT3 receptor consisting of
an extracellular domain of 5 immunoglobulin-like domains, a
transmembrane region, a cytoplasmic juxtamembrane domain
(JMD), and 2 cytoplasmic tyrosine kinase domains (TKD1 and
TKD2), interrupted by a short kinase insert [5], plays an important
role in self-renewal and differentiation of hematopoietic stem and
progenitor cells [6–8]. The JMD, that can be subdivided into the
JM-binding (JM-B) motif, the switch motif (JM-S), the linker/
zipper peptide segment (JM-Z), and the hinge region of JMD,
exerts a negative regulatory function over TKD1, consisting of
beta1-sheet, nucleotide-binding loop, beta2-sheet, and 3´of
beta2-sheet, as well as over TKD2 [5]. By disrupting the
autoinhibitory function of the JMD or mediating constitutive
phosphorylation of the TKDs, ITD mutations within JMD and
TKD1, always affecting exons 14 and 15 of FLT3 and causing in-
frame amino acid changes, lead to constitutive activation of the
receptor tyrosine kinase and its downstream signaling pathways
with consecutive dysregulated cellular proliferation [9–12]. The
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majority of ITD insertions (70%) occur within the JMD, whereas
ITDs outside the JMD integrating in the TKD1 can be detected in
~30% of ITDs most frequently affecting the beta-1 sheet of TKD1
(~25% of all ITDs) [12, 13]. Several studies have shown that ITD
mutations are associated with poor prognosis due to a high relapse
rate, in particular in cases with a high mutant to wild-type allelic
ratio (AR), commonly defined by a threshold of 0.50 using capillary
electrophoresis [14–19], and/or insertion site (IS) located in the
beta1-sheet of TKD1 [13, 18, 20].
Previous studies have demonstrated that TKD1-ITDs are
associated with resistance to chemotherapy and significantly
inferior outcome [13, 18, 20]. Here, in vitro studies showed
that non-JMD-ITDs confer resistance to a panel of FLT3 inhibitors
[21, 22]. In transfection studies performed by Arreba-Tutusaus
and colleagues, 32D cells, Ba/F3 cells, and primary mouse bone
marrow cells transduced with TKD1-ITD constructs displayed
significantly less apoptosis compared to JMD-ITD constructs
when exposed to midostaurin, and also quizartinib [22].
The natural course of FLT3 mutated AML may change with the
advent of FLT3 tyrosine kinase inhibitors (TKI) that are now
becoming increasingly available. In the CALGB 10603/RATIFY trial,
enrolling 717 FLT3 mutated (ITD and TKD) adult AML patients, the
addition of the multikinase inhibitor midostaurin to intensive
chemotherapy significantly improved overall survival (OS) and
event-free survival (EFS) [23]. The results from the trial led to the
approval of midostaurin for first-line treatment of FLT3 mutated
AML in 2017.
The aims of this large, retrospective study were to assess the
molecular landscape of FLT3-ITD and to evaluate the prognostic
impact of ITD IS on OS and cumulative incidence of relapse (CIR) in
patients enrolled on the CALGB 10603/RATIFY trial. In addition,
the predictive impact of ITD IS for response to treatment with
midostaurin was evaluated.
Patients and methods
Overall, 717 patients with AML and activating FLT3 mutations (ITD
and TKD mutations) were included in the CALGB 10603/RATIFY
trial [23]. This exploratory post-hoc analysis focused on the
prognostic and predictive impact of ITD IS in the subset of 555
FLT3-ITD positive (FLT3-ITD+) patients. Identification of FLT3-ITDs
for study entry was performed by PCR-based amplification of FLT3
exon 14 and 15 using gene-specific primers followed by capillary
electrophoresis (CE); stored biosamples for next-generation
sequencing (NGS) analysis were available in 452/555 (81%)
patients. Clinical and genetic baseline data of the patients are
given in Table 1.
Molecular analyses
FLT3-ITD mutation analysis and assessment of NPM1 mutational
status were performed as previously described [23, 24].
FLT3-ITD Roche 454 next-generation sequencing analysis
To investigate the relationship between ITD IS and patient
outcome, Roche 454 NGS analysis was performed that allowed
bi-directional sequencing with sequence read length of >500 bp
and the identification of ITDs present in less than 5% of cells.
A detailed methodological description is provided in the
Supplementary Appendix and in Supplementary Figs. 1 and 2.
Sequencing raw data were analyzed using the bioinformatics
program getITD [25].
Statistical analyses
Complete remission (CR), OS, CIR, and cumulative incidence of
death (CID) were defined by standard criteria [19]; responses
included all CRs achieved during induction therapy. Overall
survival was calculated from the date of randomization to death
of any cause. The time to relapse was calculated from the date of
first CR to relapse. Patients not having experienced the event of
interest at the end of follow-up are censored at the date of last
contact. CIR and CID were computed according to the method
described by Gray [26]. The median follow-up for survival was
calculated using the reverse Kaplan–Meier estimate [27]. Logistic
regression and Cox proportional hazards models were used to
identify prognostic variables for CR and OS [28]. CIR was analyzed
using cause-specific Cox models where death in CR is considered
as a competing event. Modeling the time to death in CR was not
possible due to a very low number of events (22 events, 19 in the
JMDsole group). Additional covariates in multivariate analysis were
IS (categorized as JMDsole, JMD/TKD1, and TKD1sole due to the
respective functional consequences and in line with previous
studies [18, 20]), treatment with midostaurin (vs placebo), and
NPM1 mutation status as dichotomous variables, as well as NGS-
based calculated FLT3-ITD AR per patients (NGS-cAR) [determined
as ∑variant allele frequency (VAF)/(100-∑VAF); log2 transformed],
number of ITDs, white blood cell (WBC) count (log2 transformed),
and age as continuous variables; allogeneic hematopoietic cell
transplantation (HCT) in first CR (CR1) was included as a time-
dependent variable. Kruskal-Wallis test was used for comparing
quantitative variables between patient subgroups; categorical
variables were compared by means of Fisher’s exact test.
Associations between continuous variables were analyzed using
the Spearman rank correlation coefficient. Survival distributions
were estimated using the Kaplan–Meier method, and differences
between groups were analyzed using two-sided log-rank tests. An
effect was considered significant if its P value was less than 5%.
The analyses were not adjusted for multiple testing. All statistical
analyses were performed with the statistical software R 4.0.2 and/
or IBM SPSS Statistics 25.
RESULTS
Patient characteristics
Table 1 summarizes the baseline characteristics of the 452 FLT3-
ITD+ patients. According to treatment arms, patients in the
placebo group exhibited more frequently a normal karyotype
(80.1% vs 62.2%; P < 0.001), NPM1 mutation (NPM1mut, 64.3% vs
50.0%; P= 0.008), and the favorable genotype NPM1mut/FLT3-
ITDlow (23.9% vs 14.7%; P= 0.031).
Next-generation sequencing
We identified a total of 908 high confidence FLT3-ITDs in the 452
patients by NGS. The median coverage (total number of
reads per patient) was 3115 (range: 482–11,616), median ITD
counts were 97 (range: 2–5234), median VAF was 3.34%
(range: 0.03–89.49%), and the median length was 45 base pairs
(bp) (range: 6–246 bp).
Molecular characterization of FLT3-ITDs
Two-hundred and ten (46.5%) of 452 FLT3-ITD+AML patients had
one ITD, and 242 (53.5%) harbored more than one ITD (2 ITDs, n=
131 [29%]; 3 ITDs, n= 58 [13%]; 4 ITDs, n= 24 [5%]; 5 ITDs, n= 18
[4%]; 6 ITDs, n= 3 [1%]; 7 ITDs, n= 7 [2%]; 9 ITDs, n= 1 [0.2%]).
All ITDs, except of 2 which exclusively affected exon 15, involved exon
14 of FLT3, and all ITDs were in-frame with a direct head-to-tail
orientation. Eighty-eight ITDs also contained intron 14, and 15 ITDs
extended to exon 15. In 619/908 (68.2%) ITDs, insertions resulted in a
change of the expected amino acid sequence at the respective site.
According to Griffith et al. [5] as well as previous and current releases
of the e!Ensembl database (release 103, February 2021: https://www.
ensembl.org/Homo_sapiens/Transcript/ProteinSummary?db=core;g=
ENSG00000122025;r=13:28003274-28100592;t=ENST00000241453),
molecular characterization of the ITDs revealed that in the majority
(70.8%, n= 643) the IS was localized in the JMD between amino
acids (aa) 573 and 609, whereas the remaining ITDs (29.2%)
inserted in 3´ direction of the JMD, predominantly in the beta1-
sheet of TKD1 between aa 610 and 615 (27.5%, n= 250) (Fig. 1A),
F.G. Rücker et al.
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which is in line with previous studies [12, 13, 18]. FLT3-ITD size was
significantly correlated with IS, in that the more C-terminal the
insertion of the IS, the longer the size of the inserted fragment
[Rho (Spearman) = 0.530; P < 0.001] (Fig. 1B).
Analysis of the duplication of specific amino acid motives
Because of the particular role of the tyrosine-rich stretch Y591 to
Y599 (YVDFREYEY) for intracellular signaling [29], we determined
the frequency of this motif in the ITDs. Duplication of at least one
residue in this specific stretch was seen in 840/908 (92.5%) ITDs.
The most frequent affected aa residues were R595 in 73.9% (n=
671), E596 (73.8%; n= 670), and Y597 (73.2%; n= 665), followed in
descending order by F594 (71.0%; n= 645), D593 (68.6%; n= 623),
E598 (66.1%; n= 600), V592 (60.7%; n= 551), Y599 (59.8%; n=
543), and Y591 (55.0%; n= 499). The entire Y591-Y599 motif was
duplicated in 265 (29.2%) ITDs. Taking patients as denominator, in
425/452 (94.0%) patients at least one ITD showed the involvement
of at least one aa of this specific motif. The entire Y591-Y599 motif
was duplicated in 117 (25.9%) patients. In Fig. 1A, length of the
ITDs, IS, and relative position of the Y591-Y599 motif within the
ITDs are illustrated.
Mutant to wild-type FLT3-ITD allelic ratio determined by NGS
(NGS-cAR)
NGS-based quantitative FLT3-ITD mutant to wild-type AR (NGS-
cAR) was calculated based on VAF as VAF/(100-VAF). The NGS-cAR
ranged from 0.0003 to 8.510, with a median of 0.04. The NGS-cAR
correlated inversely with ITD length [Rho (Spearman)=−0.087;
P= 0.009] (Fig. 1C) and aa insertion (5´ to 3´) (Rho=−0.081;
P= 0.015), in that the higher the NGS-cAR, the shorter the ITD
and the more 3´ the insertion site. NGS-cAR per patient [∑VAF/
(100-∑VAF)] ranged from 0.0006 to 10.75, with a median of
0.27 and was correlated inversely with the number of ITDs [Rho
(Spearman)=−0.142; P= 0.002], in that the higher the NGS-cAR,
the lower the number of ITD mutated clones.
Table 1. Baseline characteristics of the 452 FLT3-ITD positive patients.
All patients Midostaurin group Placebo group P value
(n= 452) (n= 230) (n= 222)
Age, years 0.090
Median 47 47 48
Range 18–60 19–59 18–60
Male sex, n/total n (%) 206 (45.6) 114/230 (49.6) 92/222 (41.4) 0.090
WBC count, ×109/l 0.497
Median 42.4 42.6 42.1
Range 0.8–329.8 0.8–304 0.8–329.8
Platelet count, ×109/l 0.910
Median 50 50.5 49.5
Range 2.0–461 2.0–461 8.0–342
Bone marrow blasts, % 0.47
Median 79 77 80
Range 3–100 3–100 6–100
Karyotype, n/total n (%) <0.001
Normal 248/348 (71.3) 107/172 (62.2) 141/176 (80.1)
Abnormal 100/348 (28.7) 65/172 (37.8) 35/176 (19.9)
2017 ELN Risk Groups, 0.138
n/total n (%)
Favorable 77/268 (28.7) 34/135 (25.2) 43/133 (32.3) 0.225
Intermediate 95/268 (35.4) 45/135 (33.3) 50/133 (37.6) 0.524
Adverse 96/268 (35.8) 56/135 (41.5) 40/133 (30.1) 0.057
NPM1 mutation, 0.008
n/total n (%) 203/358 (56.7) 95/190 (50.0) 108/168 (64.3)
Subtype of FLT3-ITD, 0.700
n/total n (%)
ITD with low AR (≤0.5)a 161/452 (35.7) 80/230 (34.8) 81/222 (36.6)
ITD with high AR (>0.5)a 290/452 (64.3) 149/230 (65.2) 141/222 (63.4)
NPM1/FLT3-ITD genotypes 0.030
n/total n (%)
NPM1mut/FLT3-ITDlow 68/357 (19.0) 28/190 (14.7) 40/167 (23.9) 0.031
NPM1mut/FLT3-ITDhigh 135/357 (37.8) 67/190 (35.3) 68/167 (40.7) 0.325
NPM1wt/FLT3-ITDlow 57/357 (16.0) 37/190 (19.5) 20/167 (12.0) 0.060
NPM1wt/FLT3-ITDhigh 97/357 (27.2) 58/190 (30.5) 39/167 (23.4) 0.153
WBC white blood cell, ELN European LeukemiaNet, AR allelic ratio.
aAssessed using Genescan analysis.















Characterization of co-occurring insertion sites
In 242 patients (54%) featuring multiple ITD clones, 698 co-occurring
IS were detected. Figure 1D illustrates the relative interaction of
concurrent IS. In detail: coexistent IS within JMD-Z were the most
frequent interaction (41.5%) followed by the interaction between
JMD-Z and beta1-sheet (20.2%), within beta1-sheet (12.2%),
between JMD-Z and hinge region (11.5%), between beta1-sheet
and hinge region (5.5%), and within the hinge region (4.8%)
(Fig. 1D). Furthermore, the vast majority of patients (204/242;
84%) with more than one ITD exhibited one dominant ITD with an
NGS-cAR at least twice as high as the sum of the NGS-cARs of the co-
insertions (Supplementary Fig. 3).
Correlation of FLT3-ITD IS with clinical baseline characteristics,
genetic features, and treatment
We correlated FLT3-ITD IS, categorized as patients having IS in (i)
JMDsole (n= 251, 55.5%), (ii) JMD/TKD1 (n= 117, 25.9%), and (iii)
TKD1sole (n= 84, 18.6%), with age, gender, WBC counts, bone
marrow (BM) blast counts, NPM1mut, FLT3-ITD AR (based on
Genescan analysis), and the four NPM1/FLT3-ITD genotypes, as
defined within the 2017 European LeukemiaNet (ELN) risk
categorization [19], number of ITDs, NGS-cAR, as well as treatment
arm (midostaurin vs placebo) and HCT in CR1. While clinical
variables did not differ among the 3 groups, JMDsole insertion
was positively correlated with NPM1mut (P= 0.028), inversely with
the NPM1wt/FLT3-ITDlow genotype (P < 0.001), and showed higher
AR, determined by both Genescan and NGS-based (P < 0.001,
each). Patients with JMD/TKD1 insertions exhibited more fre-
quently FLT3-ITDlow (AR ≤ 0.5) (P < 0.001) and had more ITD
subclones (P < 0.001). Of note, treatment with midostaurin was
more frequently performed in patients with TKD1sole insertion
(P= 0.012) (Table 2).
Clinical outcome
Response to induction therapy. Complete remission, including all
CRs during induction cycles 1 and 2, was achieved in 274/452
(60.6%) patients. To address the impact of IS on CR, correlations of
the 3 categorized IS groups [(i) JMDsole, (ii) JMD/TKD1, and (iii)
TKD1sole] were performed using a logistic regression model. This
model revealed NPM1mut as a favorable marker for achievement of
CR (OR, 2.16; 95% confidence interval [CI], 1.36–3.44; P= 0.001),
while WBC (OR for doubling of WBC, 0.83; 95% CI, 0.72–0.95; P=
0.009) and number of ITDs (OR, 0.79; 95% CI, 0.64–0.98; P= 0.035)
predicted for a lower CR rate. The 3 IS groups as well as other
variables had no impact on CR achievement (Fig. 2).
Survival analysis. The estimated median follow-up of the 452
FLT3-ITD+ AML patients was 60.6 months (95% CI, 57.4–62.9); 248
of the 452 (54.9%) patients died. Median OS time and 4-year OS
rate were 24.4 months (95% CI, 18.6–35.9 months) and 0.43 (95%
CI, 0.38–0.47), respectively. HCT in CR1 was performed in 99/452
(21.9%) patients, and overall during the disease course in 257/452
(56.9%) patients.
Survival analyses according to ITD IS showed that patients with
insertions in TKD1sole had a significantly inferior OS and a higher
CIR compared to patients with insertion sites in JMDsole and/or
JMD/TKD1 (4-year OS rates TKD1sole vs JMDsole vs JMD/TKD1:
29% vs 44% vs 50%; P= 0.032; 4-year CIR: 60% vs 45% vs 59%;
P= 0.051) (Fig. 3). Supplementary Figure 4 shows CID according to
ITD IS. In the JMD/TKD1 group, there was a significantly lower CID
rate (4-year CID rates JMD/TKD1 vs TKD1sole vs JMDsole: 4% vs
13% vs 15%; P= 0.027), providing an explanation for the
discrepancy between improved OS without decreasing the relapse
rate for this subgroup.
In Cox regression analyses on OS, FLT3-ITD IS in TKD1sole
(compared to JMDsole: HR, 1.61; 95% CI, 1.10–2.34; P= 0.014, and
compared to JMD/TKD1: HR, 2.17; 95% CI, 1.29–3.67; P= 0.004),
higher WBC (log2) (HR, 1.12; 95% CI, 1.03–1.23; P= 0.010), and
increasing age (HR, 1.17; 95% CI, 1.02–1.43; P= 0.029) revealed as
unfavorable factors for OS, whereas NPM1mut (HR, 0.58; 95% CI,
0.43–0.78; P < 0.001) and HCT in CR1 (HR, 0.46; 95% CI, 0.30–0.70;
P < 0.001) were both favorable. Multiclonality (higher number of
ITDs) (HR, 1.13; 95% CI, 0.99–1.28; P= 0.076) and higher NGS-cAR
























Fig. 1 Molecular landscape of FLT3-ITD. A correlation between ITD IS, length, as well as the relative position of the Y591-Y599 motif
(depicted in black) of the 908 ITDs sorted by IS. The duplicated fragments are color-coded according to IS and the black color demonstrates
the involvement of the amino acid motif Y591-Y599 which is important for intracellular signaling. The majority of the 908 ITDs included at
least a part of the specific amino acid stretch Y591-599. B Correlation of ITD IS with length. C Correlation of ITD length with NGS-based
calculated allelic ratio. D Circos Plot showing the interaction of concurrent IS. In 242 pts (53.5%) featuring multiple ITD clones, 698 concurrent
IS were delineated; coexistent IS within JMD-Z were the most frequent interaction (41.5%) followed by the interaction between JMD-Z and
beta1-sheet (20.2%), within beta1-sheet (12.2%), between JMD-Z and hinge region (11.5%), between beta1-sheet and hinge region (5.5%), and
within the hinge region (4.8%).
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with inferior OS. Treatment with midostaurin had no additional
impact on OS. For CIR, FLT3-ITD IS in TKD1sole (compared to
JMDsole: HR, 2.20; 95% CI, 1.34–3.59; P= 0.002), higher WBC (log2)
(HR, 1.18; 95% CI, 1.06–1.31; P= 0.003), and higher NGS-cAR (HR,
1.16; 95% CI, 1.04–1.29; P= 0.007) were associated with higher risk
of relapse, whereas NPM1mut (HR, 0.67; 95% CI, 0.45–0.98; P=
0.037) and HCT in CR1 (HR, 0.42; 95% CI, 0.26–0.69; P < 0.001)
reduced risk of relapse significantly. Treatment with midostaurin
again had no impact. The results of the Cox regression analyses
are summarized in Table 3.
Survival analyses for OS and CIR according to ITD IS and to
treatment arms are shown in Fig. 4. The 4-year rates for OS of
patients on midostaurin or placebo were 48% vs 40% (P= 0.047)
for JMDsole, 53% vs 47% (P= 0.661) for JMD/TKD1, and 32% vs
26% (P= 0.256) for TKD1sole subgroups, respectively. For CIR, the
4-year rates for patients on midostaurin or placebo were 40% vs
50% (P= 0.246) for JMDsole, 56% vs 63% (P= 0.535) for JMD/
TKD1, and 56% vs 63% (P= 0.997) for TKD1sole subgroups,
respectively.
We next performed Cox regression analyses on OS and CIR
according to the 3 IS subgroups (Table 3). Within the JMDsole group,
NGS-cAR (HR for OS, 1.18; 95% CI, 1.05–1.33; P= 0.006 and HR for
CIR, 1.45; 95% CI, 1.21–1.73; P < 0.001) and multiclonality (HR, 1.29;
95% CI, 1.04–1.60; P= 0.022 and HR, 1.43; 95% CI, 1.02–2.02; P=
0.040) had a negative impact on both OS and CIR, older age (HR,
1.24; 95% CI, 1.03–1.51; P= 0.024) on OS only, whereas treatment
with midostaurin (HR, 0.56; 95% CI, 0.37–0.84; P= 0.005 and HR,
0.57; 95% CI, 0.34–0.96; P= 0.036) and NPM1mut (HR, 0.47; 95% CI,
0.31–0.72; P < 0.001 and HR, 0.46; 95% CI, 0.27–0.78; P= 0.004) were
of beneficial impact on both endpoints. A significant beneficial
effect for HCT in CR1 was observed only for CIR (HR, 0.40; 95% CI,
0.20–0.80; P= 0.010). Within the TKD1sole group, HCT in CR1 (HR,
0.28; 95% CI, 0.12–0.68; P= 0.005 and HR, 0.19; 95% CI, 0.06–0.57;
P= 0.003) was the only significant factor for improved OS and CIR,
whereas higher WBC (log2) (HR, 1.38; 95% CI, 1.09–1.75; P= 0.008
and HR, 1.33; 95% CI, 1.04–1.70; P= 0.021) were of adverse impact
for OS and CIR. The only significant factor within the JMD/TKD1
group was HCT in CR1 (HR, 0.17; 95% CI, 0.04–0.74; P= 0.018)
associated with improved OS.
To further explore the prognostic impact of concurrent NPM1mut,
we evaluated OS and CIR according to ITD IS with or without
concurrent NPM1mut and to treatment arms. The best outcome was
observed for the genotype JMDsole/NPM1mut additionally treated
with midostaurin. The 4-year rates for OS and CIR for this genotype
on midostaurin or placebo were 65% vs 44% (P= 0.016) and 30% vs
53% (P= 0.018), respectively. The only other genotype benefitting in
trend from additional midostaurin was JMDsole/NPM1wt with 4-year
rates for OS and CIR (midostaurin vs placebo) of 40% vs 28% (P=
0.075) and 53% vs 63% (P= 0.319), respectively. There was no
benefit for additional midostaurin treatment within the other
genotypes (Supplementary Figure 5). Of note, patient numbers in
other genetic subgroups were relatively small and the study was not
powered to perform subgroup analysis. Therefore, additional
genotype-specific subgroup analyses (e.g., DNMT3A, RUNX1, etc.)
were refrained since this will result in splitting up in small subgroups
not allowing sound and meaningful statistical analyses.
Table 2. Patient and disease characteristics as well as molecular characterization, 2017 ELN risk stratification, and treatment by ITD insertion site.
JMDsole (n= 251) JMD/TKD1 (n= 117) TKD1sole (n= 84) P value
Age, median (years) 48.3 48.1 46.3 0.171
Gender, male (%) 41.0 48.7 54.8 0.067
WBC, median (range), ×109/l 40.0 (0.8–329.8) 39.9 (0.9–205.4) 53.9 (1.2–144.8) 0.254
BM blasts, median (%) 79.5 75.5 80 0.489
NPM1mut, n/total n (%) 123/195 (63.1) 46/92 (50) 34/71 (47.9) 0.028
FLT3-ITD AR risk stratification
FLT3-ITDhigh (AR > 0.5)a, n/total
n (%)
178/251 (70.9) 56/117 (47.9) 56/84 (66.7) <0.001
NPM1/FLT3-ITD genotypes 0.003
NPM1mut/FLT3-ITDlow, n/total n (%) 39/195 (20.0) 19/91 (20.9) 10/71 (14.1) 0.494
NPM1mut/FLT3-ITDhigh, n/total n (%) 84/195 (43.1) 27/91 (29.7) 24/71 (33.8) 0.069
NPM1wt/FLT3-ITDlow, n/total n (%) 18/195 (9.2) 26/91 (28.6) 13/71 (18.3) <0.001
NPM1wt/FLT3-ITDhigh, n/total n (%) 54/195 (27.7) 19/91 (20.9) 24/71 (33.8) 0.190
2017 ELN risk groups 0.473
Favorable, n/total n (%) 41/149 (27.5) 24/67 (35.8) 12/52 (23.1) 0.277
Intermediate, n/total n (%) 57/149 (38.3) 19/67 (28.4) 19/52 (36.5) 0.366
Adverse, n/total n (%) 51/149 (34.2) 24/67 (35.8) 21/52 (40.4) 0.709
No of ITDs
Median 1 3 1 <0.001
Range 1–5 2–9 1–3
NGS-based FLT3-ITD cAR
Median 0.41 0.19 0.14 <0.001
Range 0.001–10.76 0.003–4.62 0.001–2.80
Treatment
Placebo, n (%) 132 (52.6) 61 (52.1) 29 (34.5) 0.012
Midostaurin, n (%) 119 (47.4) 56 (47.9) 55 (65.5)
Allogeneic HCT in CR1, n (%) 56 (22.3) 22 (18.8) 21 (25.0) 0.562
WBC white blood cell, BM bone marrow, AR allelic ratio, ELN European LeukemiaNet.
aAssessed using Genescan analysis.




The results from this retrospective explorative analysis of the
RATIFY trial confirm the distinct molecular heterogeneity of FLT3-
ITD and the negative prognostic impact of TKD1 insertions.
Furthermore, the data show that this negative impact might not
be overcome by treatment with the multikinase inhibitor
midostaurin confirming data from earlier preclinical studies.
Additional midostaurin exerted a significant beneficial effect in
patients with IS in JMDsole, in particular with concurrent NPM1mut,
whereas no significant benefit was seen in the other patient
groups. In multivariable analysis TKD1sole insertion revealed as an
unfavorable prognostic factor for OS and CIR, whereas NPM1mut
and HCT in CR1 were associated with improved outcome.
In this large cohort of 452 younger adult AML patients, we could
confirm that ~30% of FLT3-ITDs are localized outside the JMD with a
major cluster in the beta1-sheet of the TKD1 (28%), and at very low
frequencies (≤1%) in the nucleotide-binding loop, the beta2-sheet of
the TKD1, and 3´ of the beta2-sheet [12, 13]. As previously described,
ITD size also strongly correlated with IS, in that the more C-terminal
the insertion, the longer the inserted fragment [13]. Of note, NGS-
cAR correlated inversely with (i) ITD length, (ii) the genomic insertion
(aa, 5´to 3´), and (iii) the number of ITDs per patient. While the
inverse correlation between NGS-cAR and the collinear ITD length
and genomic insertion (the higher the NGS-cAR, the shorter the ITD
and the more 5´ the IS) might be caused by the amplification
disadvantage of larger DNA fragments, the inverse correlation
between NGS-cAR and number of ITDs per patient remains elusive.
In addition, in this cohort the majority of FLT3-ITD+ AML patients
(54%) harbored more than one ITD of different leukemic subclones
which is related to the higher sensitivity of NGS compared to
conventional DNA fragment analyses [25]; 84% of these patients
exhibited one dominant FLT3-ITD clone with an NGS-cAR at least
twice as high as the sum of the NGS-cARs of the co-occurring ITDs.
In line with a previous report [13], the vast majority of patients (92%)
with >1 ITD exhibited at least one insertion within the JMD.
FLT3-ITD IS were not associated with defined clinical character-
istics, but with distinct genetic features: concurrent NPM1mut
correlated positively with IS in JMDsole, and FLT3-ITD low AR
(determined by fragment analysis) as well as number of ITDs with
the JMD/TKD1 subgroup, respectively. Moreover, we observed a
significant difference with respect to the 4 NPM1/FLT3-ITD
genotypes: The genotype NPM1wt/FLT3-ITDlow was significantly
underrepresented in the JMDsole subgroup while being highest in
the JMD/TKD1 group (Table 2).
With respect to response to induction therapy the only
favorable variable was NPM1mut known to predict for achievement
of CR, also in AML with concurrent FLT3-ITD [13, 18]. Unfavorable
factors were higher WBC counts and a higher number of ITD
clones per patient (Fig. 2). This finding is at variance to previous
studies that showed no impact for number of ITDs on response in
multivariate analyses [13, 18]. One possible explanation might be
the higher sensitivity of NGS-based ITD subclone detection as
supported by the high number of patients with >1 ITD in this
study compared to conventional fragment analysis used in the
previous studies (54% vs 14%; P < 0.001).
The first important clinical finding of this study was the
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Fig. 2 Forest plot of Odds ratios for response to induction
therapy derived by multivariate analysis by various clinical
and genetic variables. OR Odds ratio, CI confidence interval, cAR
NGS-based calculated allelic ratio.
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Fig. 3 Survival analysis for FLT3-ITD+ AML according to ITD IS. Kaplan–Meier curves for overall survival (A) and cumulative incidence of
relapse (B) for the 452 FLT3-ITD+ AML patients according to ITD IS.
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[13, 18, 20]. Multivariate analysis for OS using Cox regression in the
entire patient cohort identified TKD1sole IS, higher WBC counts,
and older age as significant unfavorable factors. Significant
favorable variables were NPM1mut and HCT in CR1 (Table 3). In
the multivariate model for hazard of relapse, TKD1sole IS, higher
NGS-cAR, and higher WBC counts predicted for higher risk of
relapse, while HCT in CR1 reduced relapse risk (Table 3). Next, we
performed multivariate analysis for OS and CIR within the 3 IS
groups. The only variable that showed a consistent favorable
effect across all subgroups was HCT in CR1 (with the exception of
JMD/TKD1 for CIR). Of note, in the JMDsole group treatment with
midostaurin – besides NPM1mut – had a strong beneficial effect on
both OS and CIR (Table 3).
The second importing finding is that the beneficial effect of
midostaurin was restricted to the JMDsole subgroup (Table 3 and
Fig. 5) being in line with preclinical data showing sensitivity to
midostaurin for JMD-ITD constructs in vitro and in vivo [22]. This
benefit might be strengthened by the significant underrepresen-
tation of the genotype NPM1wt/FLT3-ITDlow, that appears to have
no benefit from midostaurin [30], in the JMDsole subgroup
(Table 2) as well as by our data illustrating the impact of
concurrent NPM1mut on OS and CIR in the 3 IS groups and by
treatment arm (midostaurin vs placebo) (Supplementary Fig. 5).
However, these results need to be interpreted with caution
because the RATIFY trial was not powered to show statistically
significant differences in these genetic subgroups. Nevertheless,
beside the 2017 ELN risk groups our data provide evidence for
additional risk stratification based on FLT3-ITD IS.
The third interesting finding is that the negative prognostic
impact of TKD1 IS was not overcome by additional treatment
with midostaurin (Table 3, Figs. 4, 5, and Supplementary Fig. 5).
The clinical observation that patients with insertion in TKD1
might not benefit from additional midostaurin does not only
confirm the known resistance to chemotherapy of patients with
TKD1 insertions [13, 18, 20], but also to TKI treatment, which is in
line with preclinical data [21, 22]. Primary resistance of TKD1
insertions to midostaurin was first described in 2009 [21]. In a
reconstitution model it could be demonstrated that TKD1-
ITD627E was sufficient to confer resistance to a panel of FLT3
TKIs in vitro [21]. Subsequent transfection studies using 32D
cells, Ba/F3 cells, and primary mouse bone marrow cells
transduced with TKD1-ITD constructs revealed significantly
reduced apoptosis for TKD1-ITD constructs compared to JMD-
ITD constructs, when exposed to the multikinase inhibitor
midostaurin, and also to the highly selective FLT3-inhibitor
quizartinib [22]. Mechanisms mediating primary resistance of
TKD1-ITDs to TKIs being discussed are upregulation of the anti-
apoptotic myeloid cell leukemia 1 protein (MCL-1) and effective
DNA-damage repair in TKD insertions possibly protecting from
targeted and cytotoxic treatment [21, 22]. Furthermore, the
significantly higher CIR rate for patients with TKD1 insertions
compared to patients with JMDsole insertions might reflect
different patterns of clonal evolution and acquired co-mutations
mediating secondary resistance to TKIs between these groups.
Complex changes in clonal architecture underlying response
and resistance to TKI treatment have recently been described for
quizartinib and also gilterinitib [31, 32].
In conclusion, the results from this retrospective analysis of the
RATIFY trial further classify the molecular landscape of FLT3-ITD.
Using a more sensitive NGS approach we identified more than one
ITD clone in the majority of FLT3-ITD+ AML patients. Moreover,
our data confirm the negative prognostic impact of TKD1 IS that
was not significantly affected by treatment with the multikinase
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Fig. 4 Survival analysis according to ITD IS and to treatment arm. Kaplan–Meier curves for overall survival (A) and cumulative incidence of
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found for patients with JMDsole IS. In this subset, NPM1mut also
exerted a strong beneficial effect.
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